The Washington Post points the finger at Pfizer for staying mum about an Alzheimer’s study. But there’s more to the story than that
The Washington Post on Tuesday raised some provocative questions about Pfizer’s R&D operations, publishing a story that spotlights their review of research an internal group did that illustrated their blockbuster drug Enbrel could be effective in treating Alzheimer’s — the ultimate Holy Grail in an industry that has lavished billions of dollars on drug programs in search of something that could be used to bat back the disease.
This is a story of a big, bad company and its execs who had their own selfish reasons for not pursuing the research themselves. The drug is headed off-patent, say some unnamed critics, and why would Pfizer care to spend the money needed to test the theory that an anti-inflammatory could reduce risk of Alzheimer’s if it couldn’t stand to profit?
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,300+ biopharma pros reading Endpoints daily — and it's free.